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Ornithine induced more than 36-fold the omithine decarboxylase activity in confined Ehrlich ascites tumour cells after 
3.5 h of continuous perifusion with 0.5 mM omithine; arginine and glutamine also induced the activity 3- and 4-fold, 
respectively. The addition of cycloheximide or actinomycin D antibiotics to the perifusion medium confirmed that the 
regulation of the enzyme synthesis takes place at the level of translation. Perifusion in the presence of 0.5. mM omithine 
and 55, 25, and 10 PM histamine suppressed the induction by 91,53, and 35%, respectively. Similar results were obtained 
in the presence of serotonin. Histidine also showed inhibitory effect but 5 mM histidine was required to produce 21% 
inhibition; other basic amino acids were ineffective. 
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1. INTRODUCTION 
Ornithine decarboxylase (EC 4.1.1.17) is 
described as the prototype of inducible enzyme [ 11. 
It is the first key regulatory enzyme in the 
polyamine biosynthesis induced in target tissues by 
a variety of trophic agents, hormones, phar- 
maceuticals, amino acids, and cell growth stimuli 
[2]. The protein has a very rapid turnover [3]. En- 
zyme production is controlled at the translational 
level [4] by putrescine and spermidine in 
regenerating liver, hepatoma cells [5] and Ehrlich 
ascites tumour cells [6]. In addition, in rat 
hepatomas a non-competitive protein inhibitor or 
antienzyme seems to be induced by the presence of 
putrescine and other polyamines [7,8]. In Ehrlich 
ascites cell cultures 1,3_diaminopropane and some 
of its derivatives inhibit the ornithine decarbox- 
ylase induction and prevent the polyamine ac- 
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cumulation; the mechanism of action of 
aminopropanol involves the synthesis of the an- 
tienzyme protein [9]. The voluminous literature on 
the subject has been extensively reviewed by Tabor 
and Tabor 121, and Pegg [lo, 111. 
In developing HTC hepatomas, the induction of 
histidine decarboxylase (EC 4. I. 1.22) is parallel to 
the induction of the ornithine decarboxylase; both 
monofluoromethylhistamine [ 121 and the Hz recep- 
tor antagonist, cimetidine [ 131 significantly reduce 
tumour formation in mice, slowing metastatic 
development and prolonging survival [ 141. Very 
recently, Burtin et al. [15] reported the inhibition 
of tumour growth by the injection of histamine in 
both experimental tumours and cancer patients 
[ 161. The present work was undertaken to clarify 
the role of histamine and serotonin in mimicking 
the action of polyamine on ornithine decarboxylase 
induction. A very useful perifusion system [17], 
that allows the study of enzyme induction under 
steady-state conditions, was employed; low con- 
centrations of histamine and serotonin strongly in- 
hibit the induction of ornithine decarboxylase ac- 
tivity by ornithine. 
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2. MATERIALS AND METHODS 3. RESULTS 
2.1. Ehrlich ascites cells 
A hyperdiploid Lettre strain was maintained as previously 
reported [ll?]. Mice were inoculated with 5 x lo6 tumour cells 
from different infested animals; cells were harvested on the 
lOth-1 lth day after tumour transplantation at the beginning of 
the stationary growth phase [19]. Animals were killed by cer- 
vical dislocation immediately before the ascitic tumour samples 
were taken. The cells were washed once with 0.9% NaCl, and 
twice with phosphate saline buffer consisting of 6.16 mM KCI, 
154 mM NaCl, 1.65 mM NaH2P04, 9.35 mM NazHP04, pH 
7.4, centrifuged at 500 x g for 5 min. The final cell suspension 
was 4.2 x lo8 cell/ml. 
2.2. Perifusion system 
The perifusion system first described by Van der Meer [20] 
and improved by Groen et al. [21] was used with the following 
modifications [17]: the 30 ml cylindrical perifusion chamber 
was fitted with a 13 mm diameter filter of 8 pm pore size (Sar- 
torius SM M 301) placed at the top of the chamber. A magnetic 
stirrer at the bottom prevented cell deposition and clogging of 
the filter for at least 3.5 h of continuous perifusion. The 
temperature of the chamber was maintained at 37 + 1°C using 
an external heater. The perifusion system was previously filled 
with phosphate saline buffer, to which the appropriate sub- 
strates and inhibitors had been added. Buffer temperature was 
maintained at 37°C by a thermostatically controlled water bath. 
Tumour cells were quickly introduced into the chamber through 
the inlet tube to give a final cell concentration of 14 x lo6 
cell/ml. The flow rate was kept at 0.3 ml/min by means of a 
Microperpex roller pump (Pharmacia, Sweden). After 3.5 h of 
continuous perifusion, the erythrosine test revealed that cell in- 
tegrity was more than 80%. 
Fig.1 shows the short-term induction of or- 
nithine decarboxylase activity in perifused Ehrlich 
ascites cells at different intervals during 210 min of 
continuous perifusion in the presence of 0.5 mM 
ornithine. The 3.5 h perifusion time was chosen for 
all reported experiments. The addition of 0.5 mM 
ornithine induced more than 36-fold the ornithine 
decarboxylase activity, as compared with the cells 
perifused with only saline buffer in the absence of 
external source of energy or nitrogen. Under these 
conditions, glucose is avidly consumed by Ehrlich 
ascites cells [ 171, but it did not induce the enzyme 
activity (table 1). The addition of 0.5 mM arginine 
and 0.5 mM glutamine, the cellular precursors of 
ornithine, induced the ornithine decarboxylase ac- 
tivity 3- and 4-fold, respectively. The addition of 
5 mM glucose to the perifusion medium containing 
0.5 mM glutamine significantly decreased 
glutamine enzyme induction. This result could be 
explained, by the fact that the production of or- 
nithine by cells incubated in the presence of 
glutamine was decreased following the addition of 
glucose (results not shown). In all cases, the 
presence of cycloheximide suppressed the synthesis 
of ornithine decarboxylase. Nevertheless, actino- 
mycin D was ineffective. 
The addition of near physiological concentra- 
2.3. Ornithine decarboxylase assay 
After the required perifusion time, cells were extracted from 
the chamber, centrifuged at 3000 x g for 120 s, immediately 
frozen, and stored at - 20°C until use. For the ornithine decar- 
boxylase assays frozen cells were resuspended in 1.0 ml of buf- 
fer, consisting of 50 mM Hepes, 1 mM EDTA, 10 mM dithio- 
threitol, 50 FM pyridoxa15 ‘-phosphate, pH 7.2. The suspension 
was sonicated (two strokes of 20 s at high frequency ultrasonic 
oscillations) and then centrifuged at 115 000 x g for 40 min; all 
the operations were carried out at 4°C. The supernatants were 
collected and ornithine decarboxylase activity was determined 
as described by Mitchell et al. [22]. The final concentration of 
ornithine was 0.6 mM, including the 18.5 kBq of L-[1-%]or- 
nithine (spec. act. 2.22 GBq/mmol) added before each assay. 
The reactions were conducted in 7 ml conical flasks sealed with 
a rubber stopper from which hung a perforated 0.3 ml Eppen- 
dorf tube containing a paper strip (35 x 2 mm) moistened with 
1 M hyamine hydroxide in methanol. The reaction was stopped 
by the addition of 0.5 ml of 2 M citric acid. After 30 min the 
tubes containing the hyamine were transferred to scintillation 
vials for 20 min to allow the hyamine to diffuse into the scin- 
tillation liquid. Finally the samples were counted in a LKB Rack 
Beta (Sweden) scintillation counter. All assays were carried out 
in duplicate. Proteins were determined by the method of Brad- 
ford [23]. 
Fig.1. Short-term induction of ornithine decarboxylase by or- 
nithine in perifused Ehrlich ascites tumour cells. Each point 
represents the means of two different perifusions. Ornithine 
decarboxylase activity (0) expressed as nmol COz/h per lo8 
cells; activity (0) expressed as nmol COz/h per mg protein; (0) 
total protein in the cell-free extract. 
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Table 1 
Induction of ornithine decarboxylase by amino acids in perifused Ehrlich ascites tumour cells 
July 1989 
Perifusion conditions Ornithine decarboxylase activity (nmol COz/h per 10’ cells) 
Induction 
(fold) 
Actinomycin D 
(10 rg/ml) 
Cycloheximide 
(250 fig/ml) 
Saline buffer 0.12 f 0.01 (3) N.D. N.D. 
Glucose (5 mM) 0.14 f 0.01 (3) N.D. N.D. 
Glutamine (0.5 mM) 0.52 f 0.01 (4) 4.3 0.50 (2) 0.12 + 0.01 (3) 
Glucose (5 mM) + glutamine (0.5 mM) 0.27 f 0.02 (4) 2.3* N.D. N.D. 
Arginine (0.5 mM) 0.36 f 0.03 (3) 3.0 0.39 (2) 0.13 f 0.03 (3) 
Ornithine (0.5 mM) 4.32 f 0.25 (3) 36.0 4.22 f 0.11 (3) 0.15 + 0.01 (3) 
N.D., not determined. Control is the value of ornithine decarboxylase activity induced by perifusion with only saline buffer; in paren- 
theses the number of different perifusions of cells obtained from different inoculated animals. The U-Mann Witney no parametric 
significance was used: * p< 0.01 versus the value of ornithine decarboxylase activity by perifusion with only 0.5 mM glutamine 
Table 2 
Effect of histamine and serotonin on the induction by ornithine of ornithine decarboxylase 
activity in perifused Ehrlich ascites tumour cells 
Perifusion conditions Ornithine decarboxylase activity 
(nmol COz/h ner IO* cells) 
Inhibition (‘J/o) 
Ornithine (0.5 mM) 4.32 f 0.25 
Ornithine (0.5 mM) + histamine (55 PM) 0.49 f 0.03 91 
Ornithine (0.5 mM) + histamine (25 PM) 2.06 f 0.08 53 
Ornithine (0.5 mM) + histamine (10 PM) 2.80 f 0.10 35 
Ornithine (0.5 mM) + serotonin (55 PM) 0.47 f 0.01 91 
Ornithine (0.5 mM) + serotonin (IO/M) 3.25 f 0.12 24 
Control is the value of ornithine decarboxylase activity induced by perifusion with only 
0.5 mM ornithine. Values are means of three different perifusions of cells obtained from 
different inoculated animals 
Table 3 
Effect of basic amino acids on the induction by ornithine of ornithine decarboxylase activity in perifused Ehrlich 
ascites tumour cells 
Perifusion conditions Ornithine decarboxylase activity (nmol/h per lo* cells) 
% Increase % Decrease 
of control of control 
Ornithine (0.5 mM) + lysine (0.5 mM) 4.34 (2) 
Ornithine (0.5 mM) + tryptophane (0.5 mM) 4.58 (2) 8 
Ornithine (0.5 mM) + citrulline (0.5 mM) 4.44 (2) 5 
Ornithine (0.5 mM) + arginine (0.5 mM) 4.73 (2) 10 
Ornithine (0.5 mM) + histidine (0.5 mM) 3.70 f 0.05 (3) 13* 
Ornithine (0.5 mM) + histidine (5 mM) 3.39 f 0.07 (3) 21** 
Control is the value of ornithine decarboxylase activity induced by perifusion with only 0.5 mM ornithine; in 
parentheses the number of different perifusions of cells obtained from different inoculated animals. The U-Mann 
Witney no parametric significance was used: * pcO.05 versus control; ** ~~0.01 versus control 
259 
Volume 250, number 2 FEBS LETTERS July 1989 
tions of histamine [24] suppressed the induction 
caused by ornithine, when this was present in the 
perifusion medium in concentrations at least 
lo-times those of histamine (table 2). Different 
concentrations of histamine produced a clear dose- 
response ffect. Similar results were obtained in the 
perifusion experiments carried out in the presence 
of serotonin. Histidine, the cellular precursor of 
histamine also inhibited the induction of ornithine 
decarboxylase activity, but higher concentrations 
of this amino acid were needed (table 3). Indeed, 
5 mM histidine were required to produce 21% in- 
hibition. On the other hand, basic amino acids such 
as arginine, lysine, tryptophan and citrulline were 
ineffective, even when present in concentrations 
ten times those of ornithine. Moreover, in the 
presence of arginine, an additive effect was ob- 
served, because arginine alone (table 1) induced the 
ornithine decarboxylase activity. 
4. DISCUSSION 
The perifusion technique has several advantages 
over that of batch incubation in that it allows the 
continuous solution changes and also the con- 
tinuous removal of the reaction products. In those 
cases in which product inhibition occurs, batch in- 
cubation may give misleading results. Using the 
perifusion technique, the study of enzyme induc- 
tion may be carried out under steady-state condi- 
tions. Kanamato et al. [25] recently reported that 
asparagine is the most effective amino acid in 
eliciting the ornithine decarboxylase activity in 
primary cultures of hepatocytes. The degree of in- 
duction depends on the concentrations of 
asparagine; however, 10 mM asparagine are need- 
ed to produce a 20-fold increase of activity. On the 
other hand, using the perifusion technique, 
0.5 mM ornithine added to the saline buffer in- 
duced ornithine decarboxylase activity 36-fold in 
Ehrlich ascites cells. This concentration of or- 
nithine is similar to the concentration of ornithine 
found in tumour cells (unpublished results). 
The complete suppression of the induction 
caused by cycloheximide clearly indicates that the 
enzyme protein was synthesises ‘de novo’ after 
3.5 h of continuous perifusion in the presence or 
ornithine; the fact that actinomycin D had no ef- 
fect confirms once more that the ornithine decar- 
boxylase induction is regulated at the translation 
260 
level [4,11,25,26]. Many biological and synthetic 
amines are described as having a feedback control 
effect on the ornithine decarboxylase synthesis 
[6,7,27]; the histamine and serotonin effect is 
observed at micromolar concentrations in the 
presence of relatively high concentrations of the or- 
nithine inductor. The inhibitory effect of the 
amino acid histidine is probably caused via 
histamine, because cancer cells show an inducible 
histidine decarboxylase activity [28]. This effect of 
histidine on the ornithine decarboxylase induction 
might explain the inhibition of cell growth caused 
in cultured Ehrlich ascites cells by histidine [29]. 
The present results appear to explain the ex- 
perimental results of Burtin et al. [30] who have 
reported that tumour growth decreases and sur- 
vival rate increases following injections of 
histamine or serotonin in mice methylcholan- 
threne-induced fibrosarcomas. Bartholeyns and 
Fozard [31] have postulated that histamine could 
play a similar role to the biogenic amines in rapidly 
growing tissues. The present results confirm this 
hypothesis and show that histamine and serotonin 
control the induction of the ornithine decarbox- 
ylase activity and, in consequence, cell growth. 
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